[1]廖英宏,庄晓婷,白越,等.钠-葡萄糖共转运蛋白2抑制剂在血管衰老中的作用[J].国际内分泌代谢杂志,2022,42(05):373-376.[doi:10.3760/cma.j.cn121383-20210715-07038]
　Liao Yinghong,Zhuang Xiaoting,Bai Yue,et al.Roles of sodium glucose cotransporter 2 inhibitor in vascular aging[J].International Journal of Endocrinology and Metabolism,2022,42(05):373-376.[doi:10.3760/cma.j.cn121383-20210715-07038]
点击复制

钠-葡萄糖共转运蛋白2抑制剂在血管衰老中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
373-376
栏目:
综述
出版日期:
2022-09-20

文章信息/Info

Title:
Roles of sodium glucose cotransporter 2 inhibitor in vascular aging
作者:
廖英宏; 庄晓婷; 白越; 宋春莉
吉林大学第二医院心血管内科,长春 130000
Author(s):
Liao Yinghong;  Zhuang Xiaoting;  Bai Yue;  Song Chunli.
Department of Cardiology, the Second Hospital of Jilin University, Changchun 130000, China
关键词:
钠-葡萄糖共转运蛋白2抑制剂;  血管衰老;  动脉僵硬度
Keywords:
Sodium glucose cotransporter 2 inhibitor;  Vascular aging;  Vascular stiffness
DOI:
10.3760/cma.j.cn121383-20210715-07038
摘要:
血管衰老是心脑血管疾病的早期病理生理表现,与心、脑、肾及外周血管疾病等慢性病的发生发展密切相关。钠-葡萄糖共转运蛋白2(SGLT2)抑制剂是一种新型的降糖药,具有明确的心血管和肾脏保护作用。本文通过总结SGLT2抑制剂在血管衰老中的作用及相关机制,进一步了解SGLT2抑制剂对血管衰老的保护作用,以期为将来研究血管衰老及血管衰老相关疾病的干预提供新的思路。
Abstract:
Vascular aging is an early pathophysiological manifestation of cardiovascular and cerebrovascular diseases, which is closely related to the occurrence and development of chronic diseases such as heart, brain, kidney and peripheral vascular diseases. Sodium glucose cotransporter 2(SGLT2)inhibitor is a new type of hypoglycemic drug with clear cardiovascular and renal protective effects. This review summarizes the roles and mechanisms of SGLT2 inhibitors in vascular aging, which reveals the protective effect of SGLT2 inhibitors on vascular aging, as well as provides new ideas for future research on vascular aging and intervention of vascular aging related diseases.

参考文献/References:

[1] Ungvari Z,Tarantini S,Sorond F,et al.Mechanisms of vascular aging,a geroscience perspective:JACC focus seminar[J].J Am Coll Cardiol,2020,75(8):931-941.DOI:10.1016/j.jacc.2019.11.061.
[2] Park SH,Farooq MA,Gaertner S,et al.Empagliflozin improved systolic blood pressure,endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat[J].Cardiovasc Diabetol,2020,19(1):19.DOI:10.1186/s12933-020-00997-7.
[3] Khemais-Benkhiat S,Belcastro E,Idris-Khodja N,et al.Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence[J].J Cell Mol Med,2020,24(3):2109-2122.DOI:10.1111/jcmm.14233.
[4] Takahashi H,Nomiyama T,Terawaki Y,et al.Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice[J].Biochem Biophys Rep,2019,18:100640.DOI:10.1016/j.bbrep.2019.100640.
[5] Behnammanesh G,Durante GL,Khanna YP,et al.Canagliflozin inhibits vascular smooth muscle cell proliferation and migration:role of heme oxygenase-1[J].Redox Biol,2020,32:101527.DOI:10.1016/j.redox.2020.101527.
[6] Sukhanov S,Higashi Y,Yoshida T,et al.The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion[J].Cell Signal,2021,77:109825.DOI:10.1016/j.cellsig.2020.109825.
[7] Alshnbari AS,Millar SA,O'sullivan SE,et al.Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function:a systematic review of preclinical studies[J].Diabetes Ther,2020,11(9):1947-1963.DOI:10.1007/s13300-020-00885-z.
[8] Rahadian A,Fukuda D,Salim HM,et al.Canagliflozin prevents diabetes-induced vascular dysfunction in ApoE-deficient mice[J].J Atheroscler Thromb,2020,27(11):1141-1151.DOI:10.5551/jat.52100.
[9] Ortega R,Collado A,Selles F,et al.SGLT-2(sodium-glucose cotransporter 2)inhibition reduces ang II(angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE(Apolipoprotein E)Knockout Mice[J].Arterioscler Thromb Vasc Biol,2019,39(8):1614-1628.DOI:10.1161/ATVBAHA.119.312659.
[10] Herat LY,Magno AL,Rudnicka C,et al.SGLT2 inhibitor-induced sympathoinhibition:a novel mechanism for cardiorenal protection[J].JACC Basic Transl Sci,2020,5(2):169-179.DOI:10.1016/j.jacbts.2019.11.007.
[11] Sugizaki T,Zhu S,Guo G,et al.Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality[J].NPJ Aging Mech Dis,2017,3:12.DOI:10.1038/s41514-017-0012-0.
[12] Li C,Zhang J,Xue M,et al.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J].Cardiovasc Diabetol,2019,18(1):15.DOI:10.1186/s12933-019-0816-2.
[13] Wang M,Yin X,Zhang S,et al.Autoantibodies against AT1 receptor contribute to vascular aging and endothelial cell senescence[J].Aging Dis,2019,10(5):1012-1025.DOI:10.14336/AD.2018.0919.
[14] De Pascalis A,Cianciolo G,Capelli I,et al.SGLT2 inhibitors,sodium and off-target effects:an overview[J].J Nephrol,2021,34(3):673-680..DOI:10.1007/s40620-020-00845-7.
[15] Packer M.Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney:modulation by SGLT2 inhibitors and hypoxia mimetics[J].Am J Kidney Dis,2021,77(2):280-286.DOI:10.1053/j.ajkd.2020.04.016.
[16] Tomita I,Kume S,Sugahara S,et al.SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition[J].Cell Metab,2020,32(3):404-419.e6.DOI:10.1016/j.cmet.2020.06.020.
[17] Kale A,Sankrityayan H,Anders HJ,et al.Klotho:a possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes[J].Drug Discov Today,2021,26(8):1963-1971.DOI:10.1016/j.drudis.2021.04.007.
[18] Navarro-González J,Ferri C,Martín-Núñez E,et al.Therapy with sodium-glucose cotransporter type2 inhibitors increases klotho type 2 diabetic patients[J].Nephrology Dialysis Transplantation,2020,35(Supplement_3):P1008.DOI:10.1093/ndt/gfaa142.P1008.
[19] Ungvari Z,Tarantini S,Kiss T,et al.Endothelial dysfunction and angiogenesis impairment in the ageing vasculature[J].Nat Rev Cardiol,2018,15(9):555-565.DOI:10.1038/s41569-018-0030-z.
[20] Verma S,Mcmurray JJV.SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review[J].Diabetologia,2018,61(10):2108-2117.DOI:10.1007/s00125-018-4670-7.
[21] Papadopoulou E,Loutradis C,Tzatzagou G,et al.Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes:a randomized,double-blind,placebo-controlled clinical trial[J].J Hypertens,2021,39(4):749-758.DOI:10.1097/HJH.0000000000002690.
[22] Ikonomidis I,Pavlidis G,Thymis J,et al.Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes[J].European Heart Journal,2020,41(Supplement_2):2376.DOI:10.1093/ehjci/ehaa946.2376.
[23] Katakami N,Mita T,Yoshii H,et al.Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes:prespecified sub-analysis of the prospective,randomized,open-label,parallel-group comparative UTOPIA trial[J].Cardiovasc Diabetol,2021,20(1):4.DOI:10.1186/s12933-020-01206-1.
[24] Lunder M,Janic' M,Japelj M,et al.Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus[J].Cardiovasc Diabetol,2018,17(1):153.DOI:10.1186/s12933-018-0797-6.
[25] Sawada T,Uzu K,Hashimoto N,et al.Empagliflozin's ameliorating effect on plasma triglycerides:association with endothelial function recovery in diabetic patients with coronary artery disease[J].J Atheroscler Thromb,2020,27(7):644-656.DOI:10.5551/jat.50807.
[26] Sposito AC,Breder I,Soares AAS,et al.Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease:a randomized active-controlled trial[J].Cardiovasc Diabetol,2021,20(1):74.DOI:10.1186/s12933-021-01264-z.
[27] Wei R,Wang W,Pan Q,et al.Effects of SGLT-2 Inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials[J].Front Endocrinol(Lausanne),2022,13:826604.DOI:10.3389/fendo.2022.826604.
[28] Zhou H,Wang S,Zhu P,et al.Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission[J].Redox Biol,2018,15:335-346.DOI:10.1016/j.redox.2017.12.019.
[29] Ke Y,Li D,Zhao M,et al.Gut flora-dependent metabolite trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress[J].Free Radic Biol Med,2018,116:88-100.DOI:10.1016/j.Free Radic Biol Med.2018.01.007.
[30] Zhang XY,Chen J,Yi K,et al.Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity[J].Gut Microbes,2020,12(1):1-18.DOI:10.1080/19490976.2020.1842990.

相似文献/References:

[1]《钠-葡萄糖共转运蛋白抑制剂联合二甲双胍治疗型糖尿病专家共识》专家组.钠-葡萄糖共转运蛋白2抑制剂联合二甲双胍治疗2型糖尿病专家共识[J].国际内分泌代谢杂志,2023,43(05):437.[doi:10.3760/cma.j.cn121383-20230725-07036]
　Expert Group for Expert Consensus on Sodium-Glucose Cotransporter- Inhibitors with Metformin in Patients with Type Diabetes Mellitus.Expert consensus on sodium-glucose cotransporter-2 inhibitors with metformin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2023,43(05):437.[doi:10.3760/cma.j.cn121383-20230725-07036]
[2]王雪,张真稳.钠-葡萄糖共转运蛋白2抑制剂对糖尿病相关眼病的影响[J].国际内分泌代谢杂志,2024,44(03):198.[doi:10.3760/cma.j.cn121383-20230619-06036]
　Wang Xue,Zhang Zhenwen..Effects of sodium-glucose cotransporter 2 inhibitors on ocular diseases in patients with diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2024,44(05):198.[doi:10.3760/cma.j.cn121383-20230619-06036]

备注/Memo

备注/Memo:
通信作者:宋春莉,Email:songchunl@jlu.edu.cn
更新日期/Last Update: 2022-09-10